Journal of Cancer Research and Clinical Oncology最新文献

{"title":"A novel strategy for sorafenib-resistant hepatocellular carcinoma: autotaxin Inhibition by PF-8380.","authors":"Bong Jun Kwak, Jung Hyun Park, Ok-Hee Kim, Dosang Lee, Tae Ho Hong, Sang Chul Lee, Kee-Hwan Kim, Ho Joong Choi, Say-June Kim","doi":"10.1007/s00432-025-06156-3","DOIUrl":"10.1007/s00432-025-06156-3","url":null,"abstract":"<p><p>By inhibiting the conversion of lysophosphatidylcholine into lysophosphatidic acid, a process pivotal to tumor progression, the autotaxin (ATX) inhibitor PF-8380 offers a new anticancer therapeutic strategy, distinct from the action mechanism of sorafenib. This study explored the potential anticancer effects of the PF-8380 on hepatocellular carcinoma (HCC) cells, especially sorafenib-resistant strains. The investigation included both in vitro and in vivo experiments to evaluate the impact of PF-8380 treatment on epithelial-mesenchymal transition (EMT) and autophagy markers. An orthotopic HCC model served as the in vivo platform. PF-8380 showed a significant reduction in cell viability in both sorafenib-susceptible and resistant HCC cells. It effectively altered EMT by increasing E-cadherin and reducing Snail levels, and inhibited autophagy, as indicated by changes in LC3 and p62 markers. These effects were consistently observed in the orthotopic HCC mouse model, reinforcing PF-8380's potential as a dual inhibitor of EMT and autophagy in HCC treatment. Our research indicates that PF-8380 could provide substantial therapeutic benefits in the treatment of HCC, even in cases resistant to sorafenib, primarily by suppressing both EMT and autophagy processes.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"110"},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telomere length and telomerase reverse transcriptase gene polymorphism as potential markers of complete chimerism and GvHD development after allogeneic haematopoietic stem cell transplantation.","authors":"Marta Dratwa-Kuzmin, Piotr Lacina, Barbara Wysoczanska, Dorota Kilinska, Jagoda Siemaszko, Malgorzata Sobczyk-Kruszelnicka, Wojciech Fidyk, Iwona Solarska, Barbara Nasiłowska-Adamska, Patrycja Skowronska, Maria Bieniaszewska, Agnieszka Tomaszewska, Grzegorz Basak, Sebastian Giebel, Katarzyna Bogunia-Kubik","doi":"10.1007/s00432-025-06160-7","DOIUrl":"10.1007/s00432-025-06160-7","url":null,"abstract":"<p><strong>Introduction: </strong>Telomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase that maintains genome stability by maintaining telomere length (TL). The massive proliferation of donor cells in the recipient's body for engraftment results in accelerated telomere shortening. Genetic variability within the TERT gene affects telomerase activity, and was shown to influence of haematopoietic stem cell transplantation (HSCT) outcome. In the present study, we aimed to analyse the effect of recipient and donor TL and TERT single nucleotide polymorphism (SNP) on the occurrence of post-HSCT complications.</p><p><strong>Methods: </strong>Our study included 120 recipient-donor pairs. TERT promoter (TERTp) SNP (rs2853669) SNP variant was detected with the use of the LightSNiP typing assay employing real-time polymerase chain reaction (PCR) amplifications. Telomere length measurements were performed using qPCR test kits (ScienCell's Absolute Human Telomere Length Quantification qPCR Assay Kit [AHTLQ], Carlsbad, CA, USA).</p><p><strong>Results: </strong>The presence of TERTp rs2853669 T allele in the recipient was associated with a higher risk for acute graft-versus-host-disease (aGvHD) manifestation (p = 0.046) and a significantly shorter aGvHD-free survival (p = 0.041). The latter association was further confirmed in a Cox proportional hazards model (p = 0.043). However, no statistically significant association between telomere length and post-transplant complications was observed. Furthermore, we found that shorter TL characterized donors of patients with late complete chimerism at 180 day after HSCT (p = 0.011).</p><p><strong>Conclusion: </strong>Our results suggest that recipient allele TERTp rs2853669 T is a marker of unfavourable outcome in the context of aGvHD. Shorter TL in donors could be associated with later achievement of complete chimerism.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"109"},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should lymphadenectomy be recommended in radical surgery of intrahepatic cholangiocarcinoma patients? A retrospective study.","authors":"Ruoyu Zhang, Dayong Cao, Min Yang, Jiajun Zhang, Feng Ye, Ning Huang, Mei Liu, Bo Chen, Liming Wang","doi":"10.1007/s00432-025-06148-3","DOIUrl":"10.1007/s00432-025-06148-3","url":null,"abstract":"<p><strong>Purpose: </strong>Intrahepatic cholangiocarcinoma (ICC) is an extremely deadly cancer with high recurrence incidence, particularly in patients with lymph node metastasis (LNM). The necessity of lymphadenectomy including lymph node biology (LNB) and dissection (LND) during ICC radical surgery remains debate.</p><p><strong>Methods: </strong>We retrospectively analyzed the patients diagnosed with ICC and underwent radical surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences from 2012 to 2023.</p><p><strong>Results: </strong>A total of 308 ICC patients were involved in this study. pLNM⁺ group had poorer OS (P < 0.0001) and poorer DFS (P < 0.0001) compared with pLNM^- group. Compared to the LN^- group, LN⁺ group exhibited worse OS (P = 0.038) and worse DFS (P = 0.003). After PSM and IPTW, compared with LN^- group, LNB exhibited longer operation time (IPTW: P = 0.0024) and longer hospitalization days (IPTW: P = 0.0112) with no significant differences in complications, DFS, and OS. Compared with LN^- group, LND group had no better DFS and OS, only more complications (IPTW: P = 0.0191), longer operation time (all P < 0.001), higher risk of bleeding (all P < 0.05), transfusion (IPTW: P = 0.014) and longer hospitalization days (IPTW: P = 0.0044). Compared with LNB group, LND had longer operation time (P = 0.0227), higher risk of bleeding (P = 0.017) and transfusion (P = 0.0321), and more postoperative complications (P = 0.0425), with no difference in DFS and OS.</p><p><strong>Conclusion: </strong>Lymphadenectomy does not necessarily provide long-term survival or recurrence benefits. LND only achieves the effect of LNB while negatively affects postoperative recovery without survival benefit for ICC patients. LNB can be performed for accurate pathological staging while not all patients may require LND based on their specific circumstances.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"107"},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma.","authors":"Guichun Huang, Longbang Chen","doi":"10.1007/s00432-025-06103-2","DOIUrl":"10.1007/s00432-025-06103-2","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"108"},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic lymphocytic leukemia (CLL) screening and abnormality detection based on multi-layer fluorescence imaging signal enhancement and compensation.","authors":"Lemin Shi, Ping Gong, Mingye Li, Dianxin Song, Hao Zhang, Zhe Wang, Xin Feng","doi":"10.1007/s00432-025-06150-9","DOIUrl":"10.1007/s00432-025-06150-9","url":null,"abstract":"<p><strong>Purpose: </strong>Fluorescence in situ hybridization (FISH) plays a critical role in cancer screening but faces challenges in signal clarity and manual intervention. This study aims to enhance FISH signal clarity, improve screening efficiency, and reduce false negatives through an automated image acquisition and signal enhancement framework.</p><p><strong>Methods: </strong>An automated workflow was developed, integrating a dynamic signal enhancement method that optimizes global and local features. An improved Cycle-GAN network was introduced, incorporating residual connections and layer-wise supervision to accurately model and compensate for complex signal characteristics. Key metrics such as signal brightness, edge gradients, contrast improvement index (CII), and structural similarity index (SSIM) were used to evaluate performance.</p><p><strong>Results: </strong>The proposed method increased weak signal brightness by 49.02%, edge gradients by 48.61%, and CII by 32.52%. The SSIM reached 0.996, indicating high fidelity to original signals.</p><p><strong>Conclusion: </strong>Visual analysis demonstrated clearer, more continuous, and uniform fluorescence signals, effectively mitigating fragmentation and uneven distribution. These improvements reduced false negatives and enhanced genomic abnormality detection accuracy. The proposed method significantly improves FISH signal clarity and stability, providing reliable support for cancer screening, genomic abnormality detection, molecular typing, prognosis evaluation, and targeted treatment planning.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"106"},"PeriodicalIF":2.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone mineral density as potential individual prognostic biomarker in patients with neurosurgically treated spinal metastasis.","authors":"H Asoglu, T Lampmann, M Jaber, L Khalafov, J Dittmer, I Ilic, G H Gielen, M Toma, H Vatter, Z Bendella, M Schneider, C Schmeel, M Hamed, M Banat","doi":"10.1007/s00432-025-06142-9","DOIUrl":"10.1007/s00432-025-06142-9","url":null,"abstract":"<p><strong>Introduction: </strong>Bone mineral density (BMD) plays a crucial role in diagnosing and treating various systemic chronic diseases. Patients with multiple or singular spinal metastasis (SM) are typically in advanced stages of systemic cancer, often leading to significant alterations in BMD. The present study investigated the prognostic value of perioperative Hounsfield units (HU) as a surrogate independent marker for estimated BMD in patients with SM after surgical treatment (ST).</p><p><strong>Methods: </strong>HU values, serving as a surrogate for estimated BMD, were measured from circular regions of interest (ROIs) in the spine -first lumbar vertebra (L1)- from routine preoperative staging computed tomography (CT) scans in 187 patients after ST. The estimated BMD was stratified into pathologic and physiologic values and correlated with survival parameters in our cohorts.</p><p><strong>Results: </strong>Median L1 BMD of 92 patients (49%) with pathologic BMD was 79.5 HU (IQR 67.25-93.5) compared to 145 HU (IQR 123-166) for 95 patients (51%) with physiologic BMD (p ≤ 0.001). Patients with pathological BMD exhibited a median overall survival of 8 months compared to 12.2 months in patients with physiologic BMD (p = 0.006). Multivariable analysis revealed pathologic BMD as an independent negative prognostic predictor for increased 1 year mortality (AUC: 0.637, 95% CI: 0.556-0.718; p = 0.001).</p><p><strong>Conclusions: </strong>The present study demonstrates that decreased perioperative BMD values, as derived from HU measurements, may represent a previously unrecognized negative prognostic factor in patients of SM after ST. The estimated perioperative BMD could emerge as an individualized, readily available potential biomarker for prognostic, treatment, and discussion of affected patients with SM.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"105"},"PeriodicalIF":2.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of LIMK1 as a biomarker in clear cell renal cell carcinoma: from data mining to validation.","authors":"Yifei Li, Congcong Fan, Feng Jiang, Jingnan Zhang, Yanzhen Li, Yanjie Jiang, Rui Zhang, Zhixian Yu, Siqi Wang","doi":"10.1007/s00432-025-06146-5","DOIUrl":"10.1007/s00432-025-06146-5","url":null,"abstract":"<p><strong>Purpose: </strong>Clear cell renal cell carcinoma (ccRCC) is one of the most common types of renal cancer. LIM kinase 1 (LIMK1) reportedly plays an important role in tumorigenesis. However, the involvement of LIMK1 in the progression of ccRCC remains ambiguous.</p><p><strong>Methods: </strong>Based on the TCGA and CPTAC databases, the expression of LIMK1 in ccRCC was evaluated. In the TCGA-ccRCC cohort, the relationships between LIMK1 and immune cell infiltration as well as immune checkpoints were assessed. The high expression of LIMK1 in ccRCC was verified by qRT-PCR in four RCC cell lines. Immunohistochemistry was used to evaluate the expression of LIMK1 in clinical samples. The association between LIMK1 expression and survival prognosis was explored via Kaplan-Meier survival curve in the TCGA-ccRCC and local cohorts. The effects of LIMK1 knockdown on the proliferation, migration, and invasion abilities of RCC cells were evaluated via colony, CCK-8, wound healing, and Transwell assays.</p><p><strong>Results: </strong>Elevated expression level of LIMK1 was found in the TCGA-ccRCC cohort and was confirmed in RCC cell lines and clinical samples. Up-regulation of LIMK1 was found to be correlated with poor prognosis in TCGA-ccRCC and external cohorts. In addition, high-LIMK1 was associated with clinicopathological stage, immune cell infiltration and immune checkpoint in ccRCC. Importantly, knockdown of LIMK1 diminished the capability of proliferation, migration, and invasion in RCC cells.</p><p><strong>Conclusion: </strong>LIMK1 may serve as a promising diagnostic and prognostic biomarker of ccRCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"104"},"PeriodicalIF":2.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.","authors":"Can Wang, Zhengzheng Wu, Jiaying Zhou, Bin Cheng, Yulei Huang","doi":"10.1007/s00432-025-06154-5","DOIUrl":"10.1007/s00432-025-06154-5","url":null,"abstract":"<p><strong>Aims: </strong>Researches have shown that diabetes mellitus (DM) can promote the risk and progression of oral squamous cell carcinoma (OSCC). Semaglutide, a glucagon-like peptide-1 receptor agonist, is currently employed to treat type 2 diabetes mellitus (T2DM) and obesity. This study intends to explore the potential effects and mechanism of Semaglutide on OSCC.</p><p><strong>Methods: </strong>The expression of GLP-1R in OSCC cells and tissues was evaluated by qRT-PCR, western blot and immunohistochemistry assays. Cell proliferation, invasion, migration and apoptosis abilities were determined by relevant experiments. Western blot was employed to verify the expression of relevant proteins and examine the effect of Semaglutide on the MAPK signaling pathway. The xenograft transplantation model of OSCC was established to examine the anti-cancer effects of Semaglutide in vivo and immunohistochemistry assays were performed on tumor tissues.</p><p><strong>Results: </strong>GLP-1R expression was elevated in OSCC cells and tissues as compared with that in normal. Semaglutide effectively inhibited the proliferation, migration and invasion of OSCC cells while concurrently promoting apoptosis. Moreover, Semaglutide specifically activated the P38 MAPK signaling pathway without significant influence on ERK1/2 or SAPK/JNK, and its pro-apoptotic effects in OSCC cells was related to P38 pathway activation. Animal experiments verified the inhibitory effect of Semaglutide on OSCC tumors in mice.</p><p><strong>Conclusions: </strong>Semaglutide exerts inhibitory actions on OSCC and may induce apoptosis in OSCC cells via the P38 MAPK signaling pathway. This study has significant implications for the treatment of patients with diabetes who are also afflicted by OSCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"103"},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of interdisciplinary tumor boards (ITB) and personalized treatment on survival outcomes in metastatic castration-resistant prostate cancer.","authors":"Laura Lawaczeck, Anna Rüdiger, Jörg Hennenlotter, Joël Hammes, Valentina Spingler, Simon Walz, Eva Erne, Igor Tsaur, Steffen Rausch","doi":"10.1007/s00432-025-06135-8","DOIUrl":"10.1007/s00432-025-06135-8","url":null,"abstract":"<p><strong>Purpose: </strong>Interdisciplinary tumor boards (ITB) are essential in optimizing treatment recommendations for metastatic castration-resistant prostate cancer (mCRPC) by incorporating oncology guidelines, clinical trials, and patient-specific factors to ensure individualized care. This study examines clinical parameters that influence ITB recommendations, evaluates their adherence to guidelines, and assesses their impact on patient survival.</p><p><strong>Methods: </strong>In a retrospective analysis, data from 187 mCRPC patients discussed at an ITB in a tertiary care center in 2018 were evaluated. Patient- and disease-specific factors were correlated with adherence to National Comprehensive Cancer Network^® (NCCN^®) guidelines and overall survival (OS). The impact of clinical parameters on survival outcomes was assessed through univariate and multivariate analyses.</p><p><strong>Results: </strong>The median patient age was 72.8 years, with a median prostate-specific antigen (PSA) level of 65.0 ng/ml. Guideline-compliant recommendations were given in 42.9% of cases, while 57.1% received individualized recommendations. Clinical trial eligibility was noted in 24.8% of patients. Individualized ITB recommendations were associated with significantly longer OS (38.3 vs. 21.2 months, p = 0.03). Shorter OS correlated with renal impairment (p = 0.007), symptomatic metastases (p < 0.0001), and visceral metastases (p < 0.0001). Limitations include the retrospective design, lack of follow-up on therapy adherence, and absence of progression-free survival (PFS) data.</p><p><strong>Conclusion: </strong>ITB discussions improve survival in mCRPC patients, mainly due to personalized approaches and better access to clinical trials. Visceral and symptomatic metastases as well as renal impairment are risk factors for reduced OS, emphasizing the need for careful management of these high-risk patients. The results support the expanded use of ITB to improve mCRPC treatment outcomes.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"101"},"PeriodicalIF":2.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The screening value of mammography for breast cancer: an overview of 28 systematic reviews with evidence mapping.","authors":"Jiyuan Shi, Jiang Li, Ya Gao, Wanqing Chen, Liang Zhao, Ni Li, Jinhui Tian, Zheng Li","doi":"10.1007/s00432-025-06122-z","DOIUrl":"10.1007/s00432-025-06122-z","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of mammography screening in reducing breast cancer mortality and the accuracy of various mammography techniques have been widely studied. However, the quality and findings of existing systematic reviews and meta-analyses require comprehensive evaluation.</p><p><strong>Methods: </strong>A systematic literature search was conducted in the Cochrane Library, EMBASE, and PubMed for systematic reviews published up until December 20, 2022. A total of 28 systematic reviews with meta-analyses were included. Two reviewers independently extracted data and assessed methodological quality using the Risk Of Bias In Systematic Reviews (ROBIS) tool.</p><p><strong>Results: </strong>Of the 28 systematic reviews included, only 17.9% were rated as low risk of bias. The pooled estimates for breast cancer mortality reduction due to mammography screening ranged from 0.51 (95% CI 0.46-0.55) to 1.04 (95% CI 0.84-1.27). The results were influenced by study design, age, and follow-up duration, with an overall trend indicating that mammography screening reduces breast cancer mortality. Sensitivity of mammography techniques ranged from 55 to 91%, and specificity from 84 to 97%. Digital breast tomosynthesis combined with synthetic contrast-enhanced spectral mammography, digital mammography, and film mammography demonstrated relatively high cancer detection rates and low false positives.</p><p><strong>Conclusion: </strong>Mammography screening appears effective in reducing breast cancer mortality. The accuracy of various mammography techniques is generally reliable, with certain combinations showing high detection rates. However, the methodological quality of most included reviews was at high risk of bias, indicating a need for higher-quality studies in the future.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"102"},"PeriodicalIF":2.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}